Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

Published:2022-06-20 Issue:6 Volume:3 Page:710-722
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Shiba-Ishii Aya,Johnson Ted W.,Dagogo-Jack Ibiayi,Mino-Kenudson Mari^ORCID,Johnson Theodore R.,Wei Ping,Weinrich Scott L.,McTigue Michele A.,Walcott Makeba A.,Nguyen-Phuong Linh,Dionne Kristin,Acker Adam,Kiedrowski Lesli A.^ORCID,Do Andrew,Peterson Jennifer L.,Barth Jaimie L.,Yeap Beow Y.,Gainor Justin F.^ORCID,Lin Jessica J.^ORCID,Yoda Satoshi^ORCID,Hata Aaron N.^ORCID

Funder

MEXT | Japan Society for the Promotion of Science

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Lung Cancer Research Foundation

Be a Piece of the Solution Targeting a Cure for Lung Cancer Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s43018-022-00399-6.pdf

Reference32 articles.

1. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007).

2. Shaw, A. T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247–4253 (2009).

3. Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596–609 (2017).

4. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).

5. B. J. M. Solomon, T. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 373, 1582 (2015).

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage;Acta Biomaterialia;2024-09

2. Discovery of orally bioavailable ALK PROTACs based Ceritinib against ALK positive cancers;European Journal of Medicinal Chemistry;2024-09

3. EML4-ALK variant-specific genetic interactions shape lung tumorigenesis;2024-08-27

4. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

5. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3